John P. Clancy, MD, has served in several leadership roles at Univeristy of Alabama, Cincinnati Children's and within the international cystic fibrosis (CF) community. Some of his leadership roles include membership on the CFF Clinical Research Committee (2003 – present), the CFF-TDN Steering Committee (2002 – 2007), the CFF-TDN Translational Research Center Committee (2008 – present), DSMB membership for the Rare Lung Disease Consortium within the NIH Rare Disease Research Network (2005-2009, Chairman from 2010 – present)); organizing committee membership for the North American CF Conference (2003- present) and the European CF Society (2010), Co-chair of the CFFT Biomarkers Consortium (2010- present), member of the Promotion and Tenure Committee for the UAB Department of Pediatrics (2003 - 2010) and the UAB SOM (2007 – 2010, including committee Chair).
Dr. Clancy has been the primary or co-mentor of more than 20 fellows, graduate students and junior faculty. He has been the initial recipient of two endowed chairs, including the Raymond K. Lyrene Chair in Pediatric Pulmonary Medicine at the University of Alabama (2005), and the Tom Boat Chair in Cystic Fibrosis Clinical and Translational Research at Cincinnati Children's (2011).
View PubMed Publications
Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, Deboeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2011 Aug 8. Epub ahead of print.
Hug MJ, Derichs N, Bronsveld I, Clancy JP. Measurement of ion transport function in rectal biopsies. Methods Mol Biol. 2011;741:87-107.
Rowe SM, Clancy JP, Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol. 2011;741:69-86.
Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003.
Clancy JP. Diagnosing cystic fibrosis in patients with non-diagnostic results: the case for intestinal current measurements. Thorax. 2010 Jul;65(7):575-6.
Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther. 2010 Aug;23(4):268-78.
Com G, Clancy JP. Adenosine receptors, cystic fibrosis, and airway hydration. Handb Exp Pharmacol. 2009;(193):363-81.
Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs. 2009;23(3):165-74.
Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc. 2007 Aug 1;4(4):387-98.
Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol. 2007 Sep;37(3):347-56.